Call Us for Support
+91 9654860915
Finding access to medicine unapproved in your home country can feel overwhelming. We’re here to help you navigate the process, from your initial request to procurement coordination.
Submit your details and prescription to get started.Register today to get started on your medicine access journey.
Sourced directly from the authorized manufacturer network to ensure authenticity and quality.
Ready to proceed? Order Juvmo on our secure patient portal to submit your prescription, upload documents and track your approval status.
Supplied with complete CDSCO-approved import and customs documentation, including Form 12A & 12B, CDEC, GST Bill of Entry, Commercial Invoice, and Packing List.
Manufacturer / Innovator:
AbbVie Inc.
Regulatory Approval:
Your Trustworthy Partner For Named Patient Program
Over a decade of trusted expertise in Named Patient Access to innovative and life-saving medicines.
100% CDSCO-compliant processes ensuring safe, ethical, and responsible medicine access.
Medicines sourced from authorized manufacturers with full batch traceability.
EU-GDP compliant warehousing for secure, quality-controlled global distribution.
Temperature-controlled logistics ensuring safe, reliable, and timely medicine delivery.
Juvmo (tavapadon) is a once-daily tablet for Parkinson's disease in adults. The US FDA approved it in September 2026. It can be used on its own, or added to levodopa. In the trials it was studied on its own in people with early Parkinson's disease, and with levodopa in people whose levodopa effect wore off during the day (the so-called "OFF" time).
It is a prescription neurology medicine, started and adjusted by a neurologist or movement disorder specialist.
Parkinson's disease lowers dopamine in the part of the brain that controls movement. Tavapadon is a non-ergot dopamine agonist, which means it acts on dopamine receptors directly. It is selective: it works as a partial agonist only at the D1 and D5 dopamine receptors. Its half-life is about 25.5 hours, which is why one dose a day is enough.
Juvmo was tested in three 27-week, placebo-controlled studies (the phase 3 TEMPO programme).
One tablet is swallowed once daily, and food makes no difference to it. The dose is built up slowly over about six weeks with a titration pack:
From day 41, the usual maintenance dose is 5 mg once a day. If needed, the doctor may raise it by 5 mg about every 15 days, up to a maximum of 15 mg once a day. Some medicines change the dose schedule (see Warnings), so the doctor should know every medicine the patient takes.
Forgot a dose? Take it later that day once you remember. If the day has already passed, skip it and carry on the next morning as usual; two doses should never be taken together.
This information is not a treatment plan. For personalized medical advice, consult your doctor and refer to the full prescribing information.
Juvmo has no boxed warning and no contraindications in the US label. The main risks below are common to medicines that raise dopamine activity in the brain.
Juvmo can lower blood pressure, mostly when the dose is being increased. In the study with levodopa, 8% of patients had a drop in blood pressure on standing (orthostatic hypotension), against 2% on placebo. Get up slowly from sitting or lying down. Dizziness, sweating, nausea, falls or fainting should be reported.
Seeing or hearing things that are not there was reported in 3% of patients without levodopa and 7% with levodopa (placebo: 0% and 1%). The risk is higher in people aged 65 and over, and when Juvmo is taken with medicines that strongly block the CYP3A enzyme. Doctors weigh the risks carefully in people with a major psychotic illness.
Some people on Parkinson's medicines, including Juvmo, develop strong urges to gamble, shop, eat or have sex that they cannot control. Patients may not notice this themselves, so family members should tell the doctor about any new behaviour. Lowering the dose or stopping the medicine may help.
Juvmo can cause new dyskinesia or make existing dyskinesia worse. This was seen in 10% of patients taking it with levodopa, against 2% on placebo. The doctor may lower the dose of Juvmo or of the other Parkinson's medicines.
The body clears tavapadon mainly through CYP3A, an enzyme in the liver. Some antifungal, epilepsy and HIV medicines, and the herbal product St John's Wort, can raise or lower its level a great deal. With some of these the dose is taken only every 3 or every 7 days; with others the dose is split across the day; with strong inducers, use together is not recommended. Juvmo can also change the levels of some other medicines. Always show the full medicine list to the doctor and pharmacist.
There are no adequate data on Juvmo in pregnancy, and it is not known if it passes into breast milk. A woman who is pregnant, hopes to conceive or is nursing a baby should discuss this with the neurologist first. Juvmo is not approved for children.
Without levodopa: nausea (27%), headache (17%), dizziness (14%), tiredness (10%), change in taste (8%), vomiting (7%), dry mouth and anxiety (5% each). With levodopa: nausea, dyskinesia, dizziness, headache, hallucinations and low blood pressure on standing. Most people who stopped because of side effects did so while the dose was being built up. Other side effects are possible.
This information is not a treatment plan. For personalized medical advice, consult your doctor and refer to the full prescribing information.
No Indian chemist stocks Juvmo yet, so each supply is brought in for a single, named patient. Treatment begins with a 40-day titration pack and then continues every day on one fixed strength, so the very first order has to cover both stages.
We need the prescription showing two things: the titration pack to start with, and the maintenance tablet (5 mg, 10 mg or 15 mg) along with how many months it is planned for.
A registered pharmacist on our team goes through the prescription, the neurologist's Parkinson's diagnosis and the patient's identity proof. If any paper is missing or unclear, we flag it before going further.
You get one written figure for the Juvmo cost in India: the titration carton, the 30-tablet maintenance bottles for the months prescribed, air freight and customs clearance.
Our team fills in the Form 12A application, which goes to CDSCO under Rule 36 of the Drugs and Cosmetics Rules. As per CDSCO, the Form 12B licence is generally granted in one to two days, and the permit remains valid for six months.
These tablets are kept at room temperature, not in a fridge. The cartons and bottles stay factory-sealed for the whole journey and are packed to keep out summer heat.
The parcel goes to the address written on the permit, or to the neurologist's hospital if the family prefers. The first maintenance bottle reaches you before day 41, when the titration pack finishes.
Once the papers are complete, the permit itself takes around one to two working days. The arrival date for the medicine is written on your quote, because it depends on what the source has in stock and on flight connections.
Not on the Indian market. The US FDA approved tavapadon in September 2026, but CDSCO has not approved it for sale here. Indian law still allows a doctor-prescribed import for one identified patient under Rule 36, using a Form 12A application and the Form 12B permit that follows.
Almost every new patient begins with the titration pack. It is a carton of 6 weekly blister cards: 100 tablets in all, 36 of 0.25 mg and 64 of 1 mg, which covers the first 40 days. From day 41 the doctor moves the patient to one daily tablet of 5 mg, 10 mg or 15 mg, sold in 30-tablet bottles that last about a month. So the final bill depends on that strength and on how many months are prescribed.
No e-pharmacy in India can list it, since unapproved medicines are not allowed on open sale. What you can do from home is send the prescription to NPP by email or WhatsApp; we then handle the permit and bring the medicine in under the patient's own name.
Families in Nepal, Bangladesh, Bhutan, Sri Lanka and the Gulf states also write to us. Whether we can ship depends on the import law of each country. For the Indian side of the law, see our page on Indian import regulations.
AbbVie Inc. markets Juvmo in the United States. NPP works as a Juvmo supplier in India only through the named patient route: we purchase from authorised sources, and only once the Form 12B permit for that patient is in hand. That way each carton or bottle is linked to one prescription and one person.
The label asks for 20°C to 25°C, with brief spells anywhere from 15°C to 30°C allowed. In May and June that rules out the car dashboard, the kitchen shelf next to the stove and sunny windows; a cupboard in a cool room works well. Keep it where children cannot reach it. For the journey to you, we use heat-insulated packaging, explained on our temperature-controlled shipping page.
The weekly cards run out on day 40 and the next tablet is due on day 41, so we order the starter carton and the first maintenance bottles at the same time. That avoids a gap in treatment.
Before any parcel is sent out from our New Delhi office, a registered pharmacist compares it with the prescription and the permit, and makes sure the expiry date is later than the planned end of treatment.
To ask about the Juvmo price in India or how soon it can reach you, get in touch with NPP: WhatsApp +91 98104 69557, toll-free 1800-1200-365, or email info@namedpatientprogram.com.
Because Juvmo is a tablet taken at home, most families ask for delivery to their house. If the neurologist would rather keep the stock at the hospital, we send it there.
Read how our hospital delivery across India works.
Our specialists are here to guide you through every step of the medicine access process.
Mail Us At:
info@namedpatientprogram.comContact Us:
+91 9654860915Send us a message